Peinan Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Peinan Zhao has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Andrea R. Hagemann
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, Alvin J. Siteman Cancer Center, St. Louis, Missouri
92 shared publications - Carolyn K. McCourt
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri
92 shared publications - David Michael Mutch
Department of Human Health and Nutritional Sciences University of Guelph Guelph Ontario Canada
92 shared publications - Lindsay M. Kuroki
Washington University School of Medicine in St. Louis, Obstetrics and Gynecology, St. Louis, MO, US
92 shared publications - Mary M. Mullen
Washington University School of Medicine in St. Louis
92 shared publications - Premal H. Thaker
Washington University School of Medicine, St. Louis, MO, USA
92 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 8 (10)
Quantitative stress-strain cervical elastography characterizes cervical remodeling in pregnancy
- 31 July 2026
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 8 (10)
Open AccessQuantitative stress-strain cervical elastography characterizes cervical remodeling in pregnancy
- Open Access
- 12 June 2026
- Published by Elsevier in SSRN Electronic Journal
Exploring the Relationship Between Maternal Sleep Activity and Preterm Birth: A Prospective Study
Background: Preterm birth (PTB) is the leading cause of neonatal morbidity and mortality. Prior studies suggest that sleep—including short sleep duration, sleep apnea, and poor sleep quality—are associated with PTB but rely on self-reported questionnaires and diaries and provide only brief temporal snapshots susceptible to recall bias. This study used data from wearable smartwatches to obtain continuous, objective sleep measurements, enabling more accurate characterization of sleep behaviors. Methods: In this prospective longitudinal study, we evaluated whether alterations in daily rhythms during pregnancy were associated with risk for PTB. We followed a cohort of pregnant study participants enrolled early in pregnancy (< 20 weeks pregnancy) from January 2017 to January 2020 at Washington University in St. Louis Medical Center through delivery. We measured wrist movements every minute for at least 10 days during the first and second trimesters and investigated sleep and circadian metrics with risk of PTB (82 minutes (aRR=1.75, 95% CI: 1.05-2.97). Generally similar, albeit less stable, patterns of findings were observed for PTB <32 weeks’ and <28 weeks’ gestation. Notably, earlier delivery was observed only in participants above the respective threshold, leading to infinite estimates.Interpretation: These results suggest that that daily schedules may be a potential modifiable risk factor for PTB and efforts to increase the regularity of sleep could become a therapeutic strategy to ameliorate PTB.
- 12 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessExploring the Relationship Between Maternal Sleep Activity and Preterm Birth: A Prospective Study
Background: Preterm birth (PTB) is the leading cause of neonatal morbidity and mortality. Prior studies suggest that sleep—including short sleep duration, sleep apnea, and poor sleep quality—are associated with PTB but rely on self-reported questionnaires and diaries and provide only brief temporal snapshots susceptible to recall bias. This study used data from wearable smartwatches to obtain continuous, objective sleep measurements, enabling more accurate characterization of sleep behaviors. Methods: In this prospective longitudinal study, we evaluated whether alterations in daily rhythms during pregnancy were associated with risk for PTB. We followed a cohort of pregnant study participants enrolled early in pregnancy (< 20 weeks pregnancy) from January 2017 to January 2020 at Washington University in St. Louis Medical Center through delivery. We measured wrist movements every minute for at least 10 days during the first and second trimesters and investigated sleep and circadian metrics with risk of PTB (82 minutes (aRR=1.75, 95% CI: 1.05-2.97). Generally similar, albeit less stable, patterns of findings were observed for PTB <32 weeks’ and <28 weeks’ gestation. Notably, earlier delivery was observed only in participants above the respective threshold, leading to infinite estimates.Interpretation: These results suggest that that daily schedules may be a potential modifiable risk factor for PTB and efforts to increase the regularity of sleep could become a therapeutic strategy to ameliorate PTB.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 expression and platinum chemotherapy response in vitro and in patient tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 expression and platinum chemotherapy response in vitro and in patient tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Flow diagram of HGSOC patient-derived samples used for RAD51 foci assay
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Flow diagram of HGSOC patient-derived samples used for RAD51 foci assay
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 scores in BRCA mutated tumors shows correlation with survival and protein integrity
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 scores in BRCA mutated tumors shows correlation with survival and protein integrity
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE validation cohort
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE validation cohort
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer organoids
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer organoids
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
γH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
γH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer cells